We’re growing our partnerships with companies to meet the unique needs of each market, across therapeutic areas. Our interests span earlier-stage, differentiated assets through late-stage and marketed products and digital health opportunities.
Digital Health and Data Science
We partner with innovators who share our ambition to empower people to live the life they want, with better care at a reduced cost. We’re interested in scalable platforms that shorten the diagnostic journey and provide care for both common diseases and those that require specialty care.
Powered by digital technologies and data science, we aim to reverse the course of cardiovascular diseases and diabetes in the millions of people we serve by 2030. That’s what drives us to partner with entrepreneurial companies that are pioneering new possibilities.
We’re building on the success of Dupixent® in atopic dermatitis and asthma, developing new solutions for people with debilitating immuno-dermatological, rheumatic, respiratory, and gastrointestinal diseases.
Our R&D teams are working to slow or stop neurodegeneration, modulate neuroinflammation, and facilitate neuroprotection, repair, and remyelination in neurological diseases. We partner with companies with expertise in translational neuroscience and technologies.
We’re excited about our new direction in oncology and are looking for collaborations that expand our capabilities in immuno-oncology and targeted therapies. Our disease focus areas are non-small cell lung cancer, breast cancer, multiple myeloma, non-melanoma skin cancers, and colorectal cancer.
We out-license products to help partners access novel solutions, speed up time-to-market, and explore new business directions.
Our partnerships in rare diseases help us deliver solutions that have a real impact on the lives of patients. Our track record speaks for itself. We never stop working for families with rare diseases, providing hope with every breakthrough.
We’re looking for well-matched partners who can combine novel approaches with our expertise and technology platforms to rapidly advance the discovery, development, and manufacturing of new medicines.
How can we bring 10 new vaccine candidates into clinical trials by 2025? By partnering with passionate, innovative medical professionals committed to preventive care and improved public health.